Trial · NCT00091819

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819, Phase 3, Completed, Cumberland Pharmaceuticals; results first posted 2009-12-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus. Trials, record NCT00091819. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00091819

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
NCT number: NCT00091819
Status: Completed
Phases: Phase 3
Enrollment: 862 participants, actual
Lead sponsor: Cumberland Pharmaceuticals
Conditions: Staphylococcal Skin Infection
Interventions: Telavancin, Vancomycin
First posted: 2004-09-21
Last updated: 2019-01-16
Results first posted: 2009-12-08

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Clinical Response	7-14 days following end of antibiotic treatment	The Clinical Response for each patient was determined by the investigator by assessing a patient's clinical signs and symptoms at the specified evaluation compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Clinical Response	7-14 days following end of antibiotic treatment	Data for the all-treated (AT) population are presented. the AT and clinically evaluable (CE) populations were considered co-primary.	participants	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Clinical Response	Telavancin	Cure	323	participants
Clinical Response	Vancomycin	Cure	321	participants
Clinical Response	Telavancin	Not cured	52	participants
Clinical Response	Vancomycin	Not cured	58	participants
Clinical Response	Telavancin	Indeterminate	23	participants
Clinical Response	Vancomycin	Indeterminate	16	participants
Clinical Response	Telavancin	Missing	28	participants
Clinical Response	Vancomycin	Missing	34	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Telavancin	429
Overall Study	STARTED	Vancomycin	433
Overall Study	COMPLETED	Telavancin	387
Overall Study	COMPLETED	Vancomycin	387
Overall Study	NOT COMPLETED	Telavancin	42
Overall Study	NOT COMPLETED	Vancomycin	46

Source ClinicalTrials.gov

Adverse events264

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Telavancin	12	426
other	Anemia	Blood and lymphatic system disorders	Vancomycin	8	429
other	Angina Pectoris	Cardiac disorders	Telavancin	5	426
other	Angina Pectoris	Cardiac disorders	Vancomycin	1	429
other	Bradycardia	Cardiac disorders	Telavancin	2	426
other	Bradycardia	Cardiac disorders	Vancomycin	5	429
other	Cardiac failure congestive	Cardiac disorders	Telavancin	5	426
other	Cardiac failure congestive	Cardiac disorders	Vancomycin	2	429
other	Palpitations	Cardiac disorders	Telavancin	6	426
other	Palpitations	Cardiac disorders	Vancomycin	3	429

1 to 10 of 264Source ClinicalTrials.gov

See all 264 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Telavancin
Total, all-cause mortality	Vancomycin
Total, other adverse events	Telavancin	358	426
Total, other adverse events	Vancomycin	335	429
Total, serious adverse events	Telavancin	31	426
Total, serious adverse events	Vancomycin	27	429

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
18444791	RESULT	PubMed
19095213	RESULT	PubMed
22416054	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Telavancin vs Vancomycin: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00091819

GET https://conductscience.org/api/trials/v1/NCT00091819/events?page=2

API reference For AI assistants